Compare Stocks: FATE, MGTX, IMTX, and SVRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.01 -5.9%	$2.45	$0.95 ▼ $3.23	$240.24M	2.52	2.40 million shs	616,067 shs
IMTX Immatics	$6.93 -3.8%	$8.87	$6.87 ▼ $12.41	$949.31M	1.36	515,999 shs	568,010 shs
MGTX MeiraGTx	$10.04 -3.3%	$12.77	$6.62 ▼ $15.35	$963.28M	1.35	752,680 shs	478,715 shs
SVRA Savara	$4.85 +0.2%	$5.31	$3.36 ▼ $7.01	$999.56M	0.2	1.69 million shs	2.69 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-2.29%	-12.35%	-7.79%	-28.76%	+30.28%
IMTX Immatics	-2.96%	-6.73%	-17.97%	-22.89%	-30.41%
MGTX MeiraGTx	-2.90%	-4.95%	-18.84%	-16.56%	+32.40%
SVRA Savara	-1.63%	+1.26%	-8.68%	-14.94%	+43.62%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FATE Fate Therapeutics	$2.01 -5.9%	$2.45	$0.95 ▼ $3.23	$240.24M	2.52	2.40 million shs	616,067 shs
IMTX Immatics	$6.93 -3.8%	$8.87	$6.87 ▼ $12.41	$949.31M	1.36	515,999 shs	568,010 shs
MGTX MeiraGTx	$10.04 -3.3%	$12.77	$6.62 ▼ $15.35	$963.28M	1.35	752,680 shs	478,715 shs
SVRA Savara	$4.85 +0.2%	$5.31	$3.36 ▼ $7.01	$999.56M	0.2	1.69 million shs	2.69 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FATE Fate Therapeutics	-2.29%	-12.35%	-7.79%	-28.76%	+30.28%
IMTX Immatics	-2.96%	-6.73%	-17.97%	-22.89%	-30.41%
MGTX MeiraGTx	-2.90%	-4.95%	-18.84%	-16.56%	+32.40%
SVRA Savara	-1.63%	+1.26%	-8.68%	-14.94%	+43.62%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FATE Fate Therapeutics	2.38	Hold	$5.90	187.10% Upside
IMTX Immatics	2.71	Moderate Buy	$20.60	198.77% Upside
MGTX MeiraGTx	2.78	Moderate Buy	$24.71	143.85% Upside
SVRA Savara	2.89	Moderate Buy	$10.25	111.73% Upside

Current Analyst Ratings Breakdown

Latest FATE, MGTX, IMTX, and SVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C) ➝ Hold (C+)
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
9/24/2026	MGTX MeiraGTx	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
9/24/2026	MGTX MeiraGTx	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$16.00
9/22/2026	MGTX MeiraGTx	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Hold (C)
9/18/2026	IMTX Immatics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/11/2026	MGTX MeiraGTx	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
8/25/2026	IMTX Immatics	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$17.00
8/14/2026	FATE Fate Therapeutics	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$6.00 ➝ $8.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FATE Fate Therapeutics	$6.65M	37.03	N/A	N/A	$1.80 per share	1.14
IMTX Immatics	$54.60M	17.26	N/A	N/A	$4.09 per share	1.69
MGTX MeiraGTx	$81.39M	11.96	N/A	N/A	($0.07) per share	-144.79
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FATE Fate Therapeutics	-$136.32M	-$1.05	N/A	N/A	N/A	-1,941.09%	-65.08%	-41.73%	10/29/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.86	N/A	N/A	N/A	-495.71%	-47.41%	-39.45%	11/17/2026 (Estimated)
MGTX MeiraGTx	-$114.20M	$0.71	14.23	N/A	N/A	19.87%	283.85%	29.39%	11/12/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest FATE, MGTX, IMTX, and SVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.4748	-$0.53	-$0.0552	-$0.52	$12.42 million	$10.44 million
8/13/2026	Q2 2026	FATE Fate Therapeutics	-$0.2536	-$0.25	+$0.0036	-$0.25	$1.94 million	$2.08 million
8/13/2026	Q2 2026	MGTX MeiraGTx	-$0.4583	$1.71	+$2.1683	$1.71	$0.70 million	$321.43 million
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FATE Fate Therapeutics	N/A	4.85	4.85
IMTX Immatics	N/A	7.54	7.54
MGTX MeiraGTx	0.46	3.76	3.76
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FATE Fate Therapeutics	97.54%
IMTX Immatics	64.41%
MGTX MeiraGTx	67.48%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
FATE Fate Therapeutics	4.74%
IMTX Immatics	N/A
MGTX MeiraGTx	7.40%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FATE Fate Therapeutics	161	119.82 million	114.14 million	Optionable
IMTX Immatics	704	136.69 million	N/A	Optionable
MGTX MeiraGTx	393	96.04 million	88.94 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

FATE, MGTX, IMTX, and SVRA Headlines

Recent News About These Companies

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

3 hours ago | finance.yahoo.com

Savara Inc. (SVRA) - What Are Analysts Thinking About This Stock?

October 13 at 4:15 AM | americanbankingnews.com

Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

October 13 at 4:13 AM | marketbeat.com

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis ...

October 12 at 8:40 PM | joplinglobe.comJ

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12 at 4:05 PM | businesswire.com

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8, 2026 | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.

October 8, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7, 2026 | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7, 2026 | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7, 2026 | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7, 2026 | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Stock Bumped Down to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

October 4, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA

September 30, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

September 26, 2026 | marketbeat.com

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, MGTX, IMTX, and SVRA Company Descriptions

Fate Therapeutics NASDAQ:FATE

$2.00 -0.13 (-5.87%)

As of 03:24 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Immatics NASDAQ:IMTX

$6.91 -0.30 (-4.12%)

As of 03:24 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

MeiraGTx NASDAQ:MGTX

$10.02 -0.36 (-3.50%)

As of 03:24 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Savara NASDAQ:SVRA

$4.82 -0.01 (-0.31%)

As of 03:24 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, MGTX, IMTX, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, MGTX, IMTX, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, MGTX, IMTX, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, MGTX, IMTX, and SVRA Company Descriptions

Fate Therapeutics NASDAQ:FATE

Immatics NASDAQ:IMTX

MeiraGTx NASDAQ:MGTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FATE, MGTX, IMTX, and SVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FATE, MGTX, IMTX, and SVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FATE, MGTX, IMTX, and SVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, MGTX, IMTX, and SVRA Company Descriptions

Fate Therapeutics NASDAQ:FATE

Immatics NASDAQ:IMTX

MeiraGTx NASDAQ:MGTX

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools